Literature DB >> 23801934

Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations.

J Soblet1, N Limaye, M Uebelhoer, L M Boon, M Vikkula.   

Abstract

Venous malformations (VMs) are the most frequent vascular malformations referred to specialized vascular anomaly centers. A rare (1-2%) familial form, termed cutaneomucosal venous malformation (VMCM), is caused by gain-of-function mutations in TIE2. More recently, sporadic VMs, characterized by the presence of large unifocal lesions, were shown to be caused by somatic mutations in TIE2. These include a frequent L914F change, and a series of double mutations in cis. All of which cause ligand-independent receptor hyperphosphorylation in vitro. Here, we expanded our study to assess the range of mutations that cause sporadic VM. To test for somatic changes, we screened the entire coding region of TIE2 in cDNA from resected VMs by direct sequencing. We detected TIE2 mutations in 17/30 (56.7%) of the samples. In addition to previously detected mutations, we identified 7 novel somatic intracellular TIE2 mutations in sporadic VMs, including 3 that cause premature protein truncation.

Entities:  

Keywords:  Hyperphosphorylation; Receptor tyrosine kinase; Somatic mutation; Sporadic; TIE2/TEK; Vascular malformation; Venous malformation

Year:  2013        PMID: 23801934      PMCID: PMC3666452          DOI: 10.1159/000348327

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  17 in total

1.  Mutant Tie2 causing venous malformation signals through Shc.

Authors:  Paul N Morris; Benjamin J Dunmore; Nicholas P J Brindle
Journal:  Biochem Biophys Res Commun       Date:  2006-05-30       Impact factor: 3.575

2.  Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.

Authors:  Vinciane Wouters; Nisha Limaye; Melanie Uebelhoer; Alexandre Irrthum; Laurence M Boon; John B Mulliken; Odile Enjolras; Eulalia Baselga; Jonathan Berg; Anne Dompmartin; Sten A Ivarsson; Loshan Kangesu; Yves Lacassie; Jill Murphy; Ahmad S Teebi; Anthony Penington; Paul Rieu; Miikka Vikkula
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

3.  Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.

Authors:  M Vikkula; L M Boon; K L Carraway; J T Calvert; A J Diamonti; B Goumnerov; K A Pasyk; D A Marchuk; M L Warman; L C Cantley; J B Mulliken; B R Olsen
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

4.  Allelic and locus heterogeneity in inherited venous malformations.

Authors:  J T Calvert; T J Riney; C D Kontos; E H Cha; V G Prieto; C R Shea; J N Berg; N C Nevin; S A Simpson; K A Pasyk; M C Speer; K G Peters; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

5.  Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.

Authors:  Paul N Morris; Benjamin J Dunmore; Amir Tadros; Douglas A Marchuk; Diane C Darland; Patricia A D'Amore; Nicholas P J Brindle
Journal:  J Mol Med (Berl)       Date:  2004-10-29       Impact factor: 4.599

6.  Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities.

Authors:  Laurence M Boon; John B Mulliken; Odile Enjolras; Miikka Vikkula
Journal:  Arch Dermatol       Date:  2004-08

7.  Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression.

Authors:  Hsiao-Tang Hu; Yi-Hsien Huang; Yi-Ann Chang; Chien-Kuo Lee; Meei-Jyh Jiang; Li-Wha Wu
Journal:  J Invest Dermatol       Date:  2008-04-10       Impact factor: 8.551

8.  Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response.

Authors:  E I Korpelainen; M Kärkkäinen; Y Gunji; M Vikkula; K Alitalo
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

9.  Elevated D-dimer level in the differential diagnosis of venous malformations.

Authors:  Anne Dompmartin; Fanny Ballieux; Pascal Thibon; Agnès Lequerrec; Cédric Hermans; Philippe Clapuyt; Marie-Thérèse Barrellier; Franck Hammer; Daniel Labbé; Miikka Vikkula; Laurence M Boon
Journal:  Arch Dermatol       Date:  2009-11

10.  Association of localized intravascular coagulopathy with venous malformations.

Authors:  Anne Dompmartin; Aurélie Acher; Pascal Thibon; Sébastien Tourbach; Cédric Hermans; Véronique Deneys; Ben Pocock; Agnès Lequerrec; Daniel Labbé; Marie-Thérèse Barrellier; Romain Vanwijck; Miikka Vikkula; Laurence M Boon
Journal:  Arch Dermatol       Date:  2008-07
View more
  40 in total

Review 1.  New and Emerging Targeted Therapies for Vascular Malformations.

Authors:  An Van Damme; Emmanuel Seront; Valérie Dekeuleneer; Laurence M Boon; Miikka Vikkula
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

2.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

Review 3.  Female Pelvic Vascular Malformations.

Authors:  Aparna Annam
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 4.  Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.

Authors:  Ha-Long Nguyen; Laurence M Boon; Miikka Vikkula
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 5.  Classification of Vascular Anomalies: An Update.

Authors:  Jack E Steiner; Beth A Drolet
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

6.  Mutations in MC4R facilitate the angiogenic activity in patients with orbital venous malformation.

Authors:  Xiao-Ming Huang; Wan-Chen Yang; Yang Liu; Dong-Run Tang; Tong Wu; Feng-Yuan Sun
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-03

7.  Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB.

Authors:  Melanie Uebelhoer; Marjut Nätynki; Jaakko Kangas; Antonella Mendola; Ha-Long Nguyen; Julie Soblet; Catherine Godfraind; Laurence M Boon; Lauri Eklund; Nisha Limaye; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2013-04-30       Impact factor: 6.150

8.  Genotypes and phenotypes of 162 families with a glomulin mutation.

Authors:  P Brouillard; L M Boon; N Revencu; J Berg; A Dompmartin; J Dubois; M Garzon; S Holden; L Kangesu; C Labrèze; S A Lynch; C McKeown; R Meskauskas; I Quere; S Syed; P Vabres; M Wassef; J B Mulliken; M Vikkula
Journal:  Mol Syndromol       Date:  2013-03-26

9.  Diagnostic Utility of Next-Generation Sequencing for Disorders of Somatic Mosaicism: A Five-Year Cumulative Cohort.

Authors:  Samantha N McNulty; Michael J Evenson; Meagan M Corliss; Latisha D Love-Gregory; Molly C Schroeder; Yang Cao; Yi-Shan Lee; Beth A Drolet; Julie A Neidich; Catherine E Cottrell; Jonathan W Heusel
Journal:  Am J Hum Genet       Date:  2019-10-03       Impact factor: 11.025

10.  Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Authors:  Elisa Boscolo; Nisha Limaye; Lan Huang; Kyu-Tae Kang; Julie Soblet; Melanie Uebelhoer; Antonella Mendola; Marjut Natynki; Emmanuel Seront; Sophie Dupont; Jennifer Hammer; Catherine Legrand; Carlo Brugnara; Lauri Eklund; Miikka Vikkula; Joyce Bischoff; Laurence M Boon
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.